NOVO-TRIFLUZINE - TAB 5MG 5.9 MG
TRIFLUOPERAZINE HYDROCHLORIDE : 5.9 MG · DIN 00021873 · NOVOPHARM LIMITED
Health Canada status: CANCELLED POST MARKET
What is NOVO-TRIFLUZINE - TAB 5MG?
NOVO-TRIFLUZINE - TAB 5MG 5.9 MG contains TRIFLUOPERAZINE HYDROCHLORIDE : 5.9 MG. It is listed in the Health Canada Drug Product Database under DIN 00021873, held by NOVOPHARM LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 03-Jun-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What else is NOVO-TRIFLUZINE - TAB 5MG called?
The same molecule, TRIFLUOPERAZINE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Modalina | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 00021873 |
|---|---|
| Brand name | NOVO-TRIFLUZINE - TAB 5MG |
| Generic / active ingredient | TRIFLUOPERAZINE HYDROCHLORIDE : 5.9 MG |
| Manufacturer | NOVOPHARM LIMITED |
| Strength | 5.9 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N05AB06 TRIFLUOPERAZINE |
| AHFS class | 28:16.08.24 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 03-Jun-2013 |
| Original market date | 1971-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 00021873 |
|---|---|
| DIN (unpadded, as printed on some documents) | 21873 |
| Brand name | NOVO-TRIFLUZINE - TAB 5MG |
| Active ingredient / INN | TRIFLUOPERAZINE HYDROCHLORIDE : 5.9 MG |
| ATC code | N05AB06 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N05 |
| AHFS class | 28:16.08.24 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | NOVOPHARM LIMITED |
Which pack is which?
| Strength on the label | 5.9 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Is TRIFLUOPERAZINE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by AA PHARMA INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N05AB06 TRIFLUOPERAZINE. 0 of 38 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| NOVO-FLURAZINE TAB 1MG | 1.18 MG | TABLET | NOVOPHARM LIMITED | CANCELLED POST MARKET | DIN 00021857 |
| NOVO-FLURAZINE TAB 20MG | 23.6 MG | TABLET | NOVOPHARM LIMITED | CANCELLED POST MARKET | DIN 00255149 |
| NOVO-TRIFLUZINE - TAB 10MG | 11.8 MG | TABLET | NOVOPHARM LIMITED | CANCELLED POST MARKET | DIN 00021881 |
| NOVO-TRIFLUZINE - TAB 2MG | 2.36 MG | TABLET | NOVOPHARM LIMITED | CANCELLED POST MARKET | DIN 00021865 |
| PMS TRIFLUOPERAZINE HCL SYRUP 11.8MG/ML | 10 MG | SYRUP | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 00751871 |
| PMS TRIFLUOPERAZINE TAB 10MG | Strength | Tablet | PHARMASCIENCE INC 100 6111 Royalmount Ave Montreal Quebec Canada H4P 2T4 | CANCELLED POST MARKET | DIN 00726249 |
| PMS TRIFLUOPERAZINE TAB 1MG | 1 MG | TABLET | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 00726214 |
| PMS TRIFLUOPERAZINE TAB 20MG | 20 MG | TABLET | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 00726257 |
| PMS TRIFLUOPERAZINE TAB 2MG | 2 MG | TABLET | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 00726222 |
| PMS TRIFLUOPERAZINE TAB 5MG | 5 MG | TABLET | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 00726230 |
Who else supplies TRIFLUOPERAZINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TRIFLUOPERAZINE appears in 14 registered pack listings across 4 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does TRIFLUOPERAZINE cost around the world?
TRIFLUOPERAZINE is listed on 6 national price registers Nexara tracks, across 31 pack listings published on 6 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 4 | 16 | 03 Sep 2026 |
| Saudi Arabia | public | 6 | 6 | 01 Sep 2026 |
| Greece | producer price (ex-factory) | 4 | 4 | 03 Sep 2026 |
| South Africa | single exit price | 2 | 3 | 01 Sep 2026 |
| United Kingdom | hospital | 1 | 1 | 31 Aug 2026 |
| Iceland | max wholesale | 1 | 1 | 02 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.